Cargando…
Design of a Tumorigenicity Test for Induced Pluripotent Stem Cell (iPSC)-Derived Cell Products
Human Pluripotent Stem Cell (PSC)-derived cell therapy holds enormous promise because of the cells’ “unlimited” proliferative capacity and the potential to differentiate into any type of cell. However, these features of PSC-derived cell products are associated with concerns regarding the generation...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470246/ https://www.ncbi.nlm.nih.gov/pubmed/26237025 http://dx.doi.org/10.3390/jcm4010159 |
_version_ | 1782376737964818432 |
---|---|
author | Kawamata, Shin Kanemura, Hoshimi Sakai, Noriko Takahashi, Masayo Go, Masahiro J. |
author_facet | Kawamata, Shin Kanemura, Hoshimi Sakai, Noriko Takahashi, Masayo Go, Masahiro J. |
author_sort | Kawamata, Shin |
collection | PubMed |
description | Human Pluripotent Stem Cell (PSC)-derived cell therapy holds enormous promise because of the cells’ “unlimited” proliferative capacity and the potential to differentiate into any type of cell. However, these features of PSC-derived cell products are associated with concerns regarding the generation of iatrogenic teratomas or tumors from residual immature or non-terminally differentiated cells in the final cell product. This concern has become a major hurdle to the introduction of this therapy into the clinic. Tumorigenicity testing is therefore a key preclinical safety test in PSC-derived cell therapy. Tumorigenicity testing becomes particularly important when autologous human induced Pluripotent Stem Cell (iPSC)-derived cell products with no immuno-barrier are considered for transplantation. There has been, however, no internationally recognized guideline for tumorigenicity testing of PSC-derived cell products for cell therapy. In this review, we outline the points to be considered in the design and execution of tumorigenicity tests, referring to the tests and laboratory work that we have conducted for an iPSC-derived retinal pigment epithelium (RPE) cell product prior to its clinical use. |
format | Online Article Text |
id | pubmed-4470246 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-44702462015-07-28 Design of a Tumorigenicity Test for Induced Pluripotent Stem Cell (iPSC)-Derived Cell Products Kawamata, Shin Kanemura, Hoshimi Sakai, Noriko Takahashi, Masayo Go, Masahiro J. J Clin Med Review Human Pluripotent Stem Cell (PSC)-derived cell therapy holds enormous promise because of the cells’ “unlimited” proliferative capacity and the potential to differentiate into any type of cell. However, these features of PSC-derived cell products are associated with concerns regarding the generation of iatrogenic teratomas or tumors from residual immature or non-terminally differentiated cells in the final cell product. This concern has become a major hurdle to the introduction of this therapy into the clinic. Tumorigenicity testing is therefore a key preclinical safety test in PSC-derived cell therapy. Tumorigenicity testing becomes particularly important when autologous human induced Pluripotent Stem Cell (iPSC)-derived cell products with no immuno-barrier are considered for transplantation. There has been, however, no internationally recognized guideline for tumorigenicity testing of PSC-derived cell products for cell therapy. In this review, we outline the points to be considered in the design and execution of tumorigenicity tests, referring to the tests and laboratory work that we have conducted for an iPSC-derived retinal pigment epithelium (RPE) cell product prior to its clinical use. MDPI 2015-01-14 /pmc/articles/PMC4470246/ /pubmed/26237025 http://dx.doi.org/10.3390/jcm4010159 Text en © 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Kawamata, Shin Kanemura, Hoshimi Sakai, Noriko Takahashi, Masayo Go, Masahiro J. Design of a Tumorigenicity Test for Induced Pluripotent Stem Cell (iPSC)-Derived Cell Products |
title | Design of a Tumorigenicity Test for Induced Pluripotent Stem Cell (iPSC)-Derived Cell Products |
title_full | Design of a Tumorigenicity Test for Induced Pluripotent Stem Cell (iPSC)-Derived Cell Products |
title_fullStr | Design of a Tumorigenicity Test for Induced Pluripotent Stem Cell (iPSC)-Derived Cell Products |
title_full_unstemmed | Design of a Tumorigenicity Test for Induced Pluripotent Stem Cell (iPSC)-Derived Cell Products |
title_short | Design of a Tumorigenicity Test for Induced Pluripotent Stem Cell (iPSC)-Derived Cell Products |
title_sort | design of a tumorigenicity test for induced pluripotent stem cell (ipsc)-derived cell products |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470246/ https://www.ncbi.nlm.nih.gov/pubmed/26237025 http://dx.doi.org/10.3390/jcm4010159 |
work_keys_str_mv | AT kawamatashin designofatumorigenicitytestforinducedpluripotentstemcellipscderivedcellproducts AT kanemurahoshimi designofatumorigenicitytestforinducedpluripotentstemcellipscderivedcellproducts AT sakainoriko designofatumorigenicitytestforinducedpluripotentstemcellipscderivedcellproducts AT takahashimasayo designofatumorigenicitytestforinducedpluripotentstemcellipscderivedcellproducts AT gomasahiroj designofatumorigenicitytestforinducedpluripotentstemcellipscderivedcellproducts |